trending Market Intelligence /marketintelligence/en/news-insights/trending/been-nfk2dhadzamn7vrla2 content esgSubNav
In This List

Halozyme Therapeutics director to step down

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Halozyme Therapeutics director to step down

Randal Kirk informed Halozyme Therapeutics Inc. of his unavailability to serve as a director due to his growing commitments outside of the company.

Due to this development, Kirk will not be nominated for re-election to the board at the upcoming stockholders' annual meeting.

San Diego, Calif.-based Halozyme Therapeutics is a biotechnology company which researches, develops, and commercializes human enzymes and other drug candidates in the U.S., Switzerland, and internationally.